The implications of glucocorticoid-activated GR signaling upregulating oncoproteins associated with tumor progression and therapy resistance are far-reaching and have the potential to impact PCa patients who may have elevated levels of endogenous cortisol or a propensity for hypersensitive GR signaling. The gene discussed is NR3C1; the disease is posterior cortical atrophy.